Drug resistance in patients experiencing early virological failure under a triple combination including indinavir.
about
Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort StudyDevelopment of a macrophage-based nanoparticle platform for antiretroviral drug delivery.Provider-focused intervention increases adherence-related dialogue but does not improve antiretroviral therapy adherence in persons with HIVVirological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in SwedenGenotypic testing for human immunodeficiency virus type 1 drug resistance.Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts.Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance.Comparison of sequential three-drug regimens as initial therapy for HIV-1 infectionComparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study.Antiretroviral medication adherence and the development of class-specific antiretroviral resistance.Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.The pharmacology of HIV drug resistance.Time to Viremia for Patients Taking their First Antiretroviral Regimen and the Subsequent Resistance Profiles.Efficiency of a programmed -1 ribosomal frameshift in the different subtypes of the human immunodeficiency virus type 1 group M.Is average adherence to HIV antiretroviral therapy enough?Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance.British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005).
P2860
Q28534423-A8885CDE-906E-4D0D-8104-41C849986806Q30479638-BCCAABE4-A494-4AD4-9F08-40921695B145Q33703513-7C116A9D-D2E9-41D0-904E-70439498DB67Q33856712-27E4ADA9-DBCF-48A9-ACD4-568F438F6A98Q33906239-356EF4E9-1375-4340-BE78-067011B85280Q34087809-92B2C2D2-4564-4733-BA47-837F01F40607Q34789834-4A92E3DD-8353-4395-AC8C-22E82CFAD0D8Q35237575-4B2C10E2-B98C-448B-906F-4C91519E60FBQ36618299-98925835-10CF-4611-8AE9-57463AEDC63DQ36623603-762A4F3A-5A50-464B-A71B-8784BA8E23CFQ37175647-ACA35FD6-DD94-4CBC-A23B-731ECC9B541CQ37246452-7F82BA32-6E2A-46D7-AEBD-67D2FCB4A5CFQ37823558-62E67C56-EC04-4CDE-818D-20DD8B60D9FBQ39133627-54ABD72B-A8E8-463C-BDA3-8EF96369613CQ40783234-CA9A41F5-08CF-46DC-B444-2848A8BFE147Q41848089-E12A2F96-EAFA-45BD-8DC2-5E39C32DFC9CQ42347783-B27AC20F-F6D8-4C0A-8D9F-936582FFE942Q44183256-D428F741-9ECF-44E6-8126-6213FEB02E36Q45060352-4D1EBE1C-17AD-46AA-A857-C291B037A3C1Q45710950-2A6FFB56-85F7-4C3F-BA8E-9A2D483B758AQ53851252-4FF50182-BA6E-454A-92B3-058BD18F80C8
P2860
Drug resistance in patients experiencing early virological failure under a triple combination including indinavir.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Drug resistance in patients ex ...... mbination including indinavir.
@en
Drug resistance in patients ex ...... mbination including indinavir.
@nl
type
label
Drug resistance in patients ex ...... mbination including indinavir.
@en
Drug resistance in patients ex ...... mbination including indinavir.
@nl
prefLabel
Drug resistance in patients ex ...... mbination including indinavir.
@en
Drug resistance in patients ex ...... mbination including indinavir.
@nl
P2093
P1433
P1476
Drug resistance in patients ex ...... mbination including indinavir.
@en
P2093
García-Arata I
Guardiola JM
Gónzalez J
Pedreira J
Pérez-Elías MJ
P304
P356
10.1097/00002030-200109070-00014
P407
P577
2001-09-01T00:00:00Z